JP2014058479A - Product to suppress inhalation of harmful substances - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a product to suppress inhalation which prevents appearance of symptoms due to harmful substances even if the harmful substances once adsorbed are detached and inhaled by humans, thereby achieving sufficient effect to suppress inhalation of harmful substances.SOLUTION: A product to suppress inhalation of harmful substances for suppressing inhalation of harmful substances such as allergens and pathogenic viruses by humans, comprises an electrically charged substance which is electrically charged to adsorb harmful substances by Coulomb force, and an inactivation agent to inactivate the harmful substances adsorbed to the electrically charged substance.

Description

  The present invention relates to an inhalation-suppressing product for harmful substances that inhibits humans from inhaling harmful substances such as allergens and pathogenic viruses.

  For example, Patent Document 1 discloses a topical nasal product that suppresses inhalation of contaminants in the air into a human nostril. According to the description of Patent Document 1, an electrostatic region is created around the nostril by applying a charged substance around the human nostril and its periphery, thereby preventing contaminants in the air from approaching the nostril. , Adsorb and suppress the inhalation of pollutants.

Japanese Patent No. 4870431

  By the way, according to the topical nasal product of Patent Document 1, allergens such as dead mites, feces and pollen, and harmful substances such as pathogenic viruses are adsorbed around the nostril, which causes humans to inhale. It is thought that this can be suppressed.

  However, harmful substances adsorbed around the nostrils are still considered active. This active toxic substance, for example, is affected by the airflow when a person moves, or when he touches his face with his hand, he leaves the nostrils and can be inhaled from the mouth or in the eyes. Yes, this will cause symptoms due to harmful substances, and as a result, the inhalation suppression effect will be insufficient.

  The present invention has been made in view of such points, and the purpose of the present invention is to prevent symptoms caused by harmful substances from appearing even if once adsorbed harmful substances are separated and inhaled by humans. The objective is to obtain a sufficient inhalation-suppressing effect for harmful substances.

  In order to achieve the above object, in the present invention, the adsorbed harmful substances are deactivated.

The first invention relates to an inhalation suppression product for harmful substances that suppresses human inhalation of harmful substances such as allergens and pathogenic viruses,
A charged substance having a charge to adsorb the harmful substance by Coulomb force;
And a deactivator for deactivating the harmful substance adsorbed on the charge substance.

  According to this configuration, when a charged substance is attached to the face, harmful substances in the air are adsorbed to the charged substance by Coulomb force. The harmful substance adsorbed on the charge substance is deactivated by the deactivator. Therefore, even if the harmful substance once adsorbed to the charged substance is separated from the charged substance and inhaled by humans, the symptoms caused by the harmful substance do not appear.

According to a second invention, in the first invention,
The quencher is a rutile type titanium oxide.

  According to this configuration, it is possible to deactivate harmful substances while ensuring high safety in the human face.

According to a third invention, in the first or second invention,
The charged substance and the quencher are dispersed in a liquid,
It has a spray mechanism for spraying a liquid in which the charge substance and the deactivator are dispersed.

  According to this configuration, it becomes possible to easily apply the charged substance and the deactivator so as not to cause unevenness in a wide range of the face.

  According to the first invention, since the deactivating agent for deactivating the harmful substance is included, the detrimental substance adsorbed on the charge substance can be deactivated. As a result, even if the harmful substance once adsorbed to the charged substance is separated from the charged substance and inhaled by humans, symptoms of the harmful substance can be prevented from appearing and the inhalation effect of the harmful substance can be sufficiently suppressed. Can get to.

  According to the second invention, since the rutile type titanium oxide is used as the deactivator, harmful substances can be deactivated while ensuring high safety when used on a human face.

  According to the third invention, since the liquid in which the charge substance and the deactivator are dispersed is sprayed, the charge substance and the deactivator can be easily applied so as not to cause unevenness in a wide range of the face. In addition, the effect of suppressing the inhalation of harmful substances can be further enhanced.

It is a figure which shows the inhalation suppression product of the hazardous | toxic substance concerning embodiment of this invention. It is a figure explaining the point of use of the inhalation suppression product of a harmful substance. It is a graph which shows the electrical potential difference at the time of apply | coating a chemical | medical agent with a finger | toe, and the case where it apply | coats with a spray mechanism. It is a figure which shows typically the effect | action of a chemical | medical agent. It is a graph which shows the difference of the symptom when not apply | coating a chemical | medical agent and when apply | coating. It is a graph which shows the amount of pollen inhalation when not applying a medicine and when applying.

  Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings. It should be noted that the following description of the preferred embodiment is merely illustrative in nature, and is not intended to limit the present invention, its application, or its use.

  FIG. 1 shows an inhalation suppression product 1 for harmful substances according to an embodiment of the present invention. The harmful substance inhalation suppression product 1 is for suppressing inhalation of harmful substances by humans and is mainly used for the face. Toxic substances are allergens such as dead mites, feces, pollen, and pathogenic viruses that float in the air. When these harmful substances are inhaled and taken into the body, symptoms such as asthma, dermatitis, and hay fever may appear. The harmful substances targeted by the present invention are not limited to the above, and include substances that exhibit some symptoms when taken into the body. Most of the harmful substances mentioned above usually have a positive or negative charge.

  The harmful substance inhalation suppression product 1 includes a container 1, a liquid medicine accommodated in the container 1, and a spray mechanism (attachment means) 3 for spraying the medicine in the container 1. The spray mechanism 3 is a push spray type configured to suck and spray the medicine in the container 1 when the user pushes it with a finger, and directly attaches the medicine to the human face without using a finger. It can be made to. The spray mechanism 3 may be a trigger type as long as it can spray a medicine. The amount of the medicine to be ejected by one operation is set to 0.15 ml, for example, and the usage amount per time is set to 0.3 ml by two ejection operations. The amount ejected by one operation and the amount used per time are not limited to the above, and can be set, for example, in the range of 0.1 ml to 0.5 ml.

  The drug includes a charged substance having a charge that gives a Coulomb force to the harmful substance, a deactivator that deactivates the harmful substance, and water in which the charge substance and the deactivator are dispersed. The charge substance may be a charge substance having a positive charge or a charge substance having a negative charge. In this embodiment, cationized cellulose is used as a charge substance having a positive charge. Other charged substances having a positive charge include, for example, cationized starch, polymethacryloylaminopropyltrimethylammonium chloride, ethyl lanolin fatty acid aminopropylethyldimethylammonium salt, quaternary ammonium salt, and other cationic surfactants. These may be used alone or in combination of two or more. Examples of the negatively charged substance include anionic surfactants such as phosphate esters and sodium dodecyl sulfate. The charged substance is preferably a highly safe substance that does not cause irritation even if it adheres to the face. Further, the mixing amount of the charge substance is preferably 0.01 to 10.0 parts by weight.

  Examples of the deactivator include titanium oxide and hectorite. According to titanium oxide, harmful substances can be deactivated (inactivated) by the photocatalytic function of titanium oxide. In other words, by applying light energy to titanium oxide, a strong oxidizing power is expressed on the surface of titanium oxide, and it is possible to decompose and deactivate harmful substances touching titanium oxide using this oxidizing power. is there.

  There are anatase type and rutile type as the crystal type of titanium oxide, but the rutile type is preferable in consideration of both safety on the face and deactivation ability. The average particle diameter of titanium oxide is preferably 1 nm or more and 200 nm or less from the viewpoint of obtaining sufficient deactivation ability. More preferably, it is 10 nm or more and 100 nm or less. When the average particle size is smaller than 1 nm, there is a problem that the contact portion with harmful substances becomes small, and it becomes difficult to obtain sufficient deactivation ability, and when the average particle size is larger than 200 nm, There is a problem that it is difficult to formulate because precipitation is likely to occur. A plurality of types of titanium oxide having different average particle diameters may be mixed and used as a deactivator. The titanium oxide used may be coated with a surface treatment agent such as silicic acid, aluminum, or silica.

  When the deactivator is hectorite, a harmful substance is taken into the layered structure of hectorite, and as a result, the harmful substance is deactivated. As a quencher, both titanium oxide and hectorite may be used. Moreover, as a mixing amount of deactivation, 0.01-10.0 weight part is preferable.

  In addition to the charge substance and the quenching agent, additives such as a fragrance may be added to the drug. Examples of the type of additive include powder, moisturizer, preservative and the like. Further, the amount of the additive added differs depending on the type and the like and cannot be determined unconditionally. However, it is preferable to determine the amount of the additive within a range in which the object of the present invention is not hindered.

  Moreover, you may add the component as a sunscreen, an anti-inflammatory component, etc. to a chemical | medical agent. These addition amounts can also be set arbitrarily.

  The spray mechanism 3 is configured such that the average particle diameter of the medicine to be sprayed is 50 μm or more and 200 μm or less. The average particle diameter of the medicine can be arbitrarily set depending on the shape and size of the injection port of the spray mechanism 3. If the average particle size is smaller than 50 μm, it tends to be scattered during spraying of the drug, and there is a problem that the amount of adhesion to the target location is reduced, and if the average particle size is larger than 200 μm, the drug is liquid. Since it adheres to the skin with droplets, there is a problem that uniform application becomes difficult and the usability is remarkably deteriorated.

  The method for measuring the average particle size of the drug is as follows. The medicine was jetted from the jetting mechanism 3 in the horizontal direction, and the average particle diameter at a location 20 cm away from the jetting port in the jetting direction (horizontal direction) by a linear distance was measured. The ambient temperature is 25 ° C. A particle size distribution measuring device (laser light scattering method, LDSA-1400A manufactured by Tohnichi Computer Applications Co., Ltd.) was used as the average particle size measuring device. The average particle diameter means D50 measured by the particle size distribution measuring apparatus, automatically calculated by the processing apparatus and analyzed. D50 is the particle diameter when the volume integrated value occupies 50%. The starting point of the linear distance is the center point of the injection port.

  In this embodiment, the medicine is sprayed by utilizing the pump action by the pressing operation of the user. However, the invention is not limited to this, and the medicine is stored together with the propellant in a so-called aerosol can, and the button is operated. The medicine may be jetted together with the propellant. Examples of the propellant include, but are not limited to, a compressed gas such as nitrogen and carbon dioxide, and a liquefied gas such as LPG and DME.

  Next, the case where the inhalation suppression product 1 for harmful substances configured as described above is used will be described. Since the harmful substance inhalation suppression product 1 includes the spray mechanism 3 as described above, the user can operate the spray mechanism 3 to spray the medicine in the form of a mist (see FIG. 2). . That is, in this embodiment, the medicine can be directly applied to the face. The advantage of this will be described with reference to FIG.

  FIG. 3 is a graph showing how much the potential changes with time when the drug is applied to the human skin with a finger and when the drug is applied by the spray mechanism 3. The horizontal axis indicates the elapsed time (minutes), and the vertical axis indicates the amount of change in the skin surface potential. The amount of change in potential is indicated by an index that is a relative comparison with the potential of the skin surface where nothing is applied.

  Immediately after application, it is 1.5 when applied with a finger, whereas it is 2.5 when the spray mechanism 3 is used, and a large potential difference is generated. When applied with a finger, the potential rapidly decreases with time, whereas when the spray mechanism 3 is used, the degree of decrease is gradual. The potential of about 7 times that applied in the above is maintained.

  When applying with a finger, when the substance adhering to the finger touches the charged substance, it may act in a direction that reduces the charge of the charged substance, so the potential when applied with the finger is low. Become.

  In this embodiment, since it is not applied with a finger, even if a substance that reduces the charge possessed by the charged substance is attached to the finger in a situation where the hand cannot be washed like when going out, as shown in FIG. A high potential can be maintained for a long time.

  Further, by using the spray mechanism 3, it is possible to apply the medicine uniformly over a wide range such as the cheek of the face and the forehead.

  On the facial skin, as shown schematically in FIG. 4, the charged substance A and titanium oxide B are present in a wide range. When pollen C having a negative charge is floating in the air, the charge of charged substance A gives Coulomb force to pollen C. Since the charged substance A and the pollen C have different signs, the pollen C is adsorbed by the charged substance A. Pollen C adsorbed on the charged substance A is decomposed and deactivated by the oxidizing power of titanium oxide B under an environment where light is applied. In addition to adsorbing pollen C in this way, when deactivated, for example, when pollen C once adsorbed on charged substance A is separated from charged substance A for some reason and is inhaled into the body from the mouth, Since the pollen C has already been inactivated, no allergic symptoms appear.

  On the other hand, even when pollen D having a positive charge is floating in the air, the charge of charged substance A gives Coulomb force to pollen D. The Coulomb force at this time is a repulsive force because the charged substance A and the pollen D have the same sign. Therefore, pollen D leaves the charged substance A (the face surface) and is not inhaled into the body. As shown in FIG. 3, since a high potential is maintained on the surface of the face, the adsorptive power of pollen C and the repulsive power of pollen D become large, and the above-described action can be sufficiently obtained. In addition, pathogenic virus etc. are similarly adsorbed and deactivated, or move away from the face surface.

  Since pollen, virus, and the like are inactivated on the surface of the skin, attacks on the skin by pollen, virus, etc. are reduced. Therefore, the harmful substance inhalation suppression product 1 is also effective for the skin.

  The effect of this embodiment is demonstrated based on FIG.5 and FIG.6. FIG. 5 shows how much the symptom changes depending on whether or not the medicine is applied for each of the pollen allergy eye symptom and nasal symptom. There are 12 test subjects, and the test method has a 7-day non-treatment period (period in which no drug is applied) and a 7-day drug treatment period (period in which the drug is applied). It is a method to have you fill out. The symptom score is 5 levels (0 is no symptom, 1 is mild, 2 is light, and nasal symptoms (sneezing, runny nose, nasal congestion, nasal itch) 3 was bad and 4 was very bad).

  As is apparent from the figure, application of the drug alleviates both eye symptoms and nasal symptoms. This indicates that pollen is not only adsorbed by the charged substance, but also deactivated after adsorption, so that even if it is inhaled, it is difficult to show symptoms.

  FIG. 6 is a graph comparing pollen inhalation amounts when the drug is not applied and when the drug is applied. In the test method, a model of a human nose made of silicon rubber was prepared, the model was placed in the air in which pollen floated, and the amount of pollen captured by inhaling air from the nose of the model was counted. Pollen amount is shown as an index. The drug is applied around the nose of the model. As is clear from this figure, the ability of adsorbing pollen by the drug is sufficiently high, and the amount of pollen inhalation is reduced by 30% or more compared to the case where the drug is not applied.

  As described above, according to the harmful substance inhalation suppression product 1 according to this embodiment, since the deactivating agent that deactivates the harmful substance is included, the harmful substance adsorbed on the charge substance is deactivated. Can do. As a result, even if the harmful substance once adsorbed to the charged substance is separated from the charged substance and inhaled by humans, symptoms of the harmful substance can be prevented from appearing and the inhalation effect of the harmful substance can be sufficiently suppressed. Can get to.

  Further, since rutile type titanium oxide is used as the quenching agent, harmful substances can be deactivated while ensuring high safety when used on a human face.

  Further, since the liquid in which the charged substance is dispersed is sprayed, the charged substance can be easily applied so as not to cause unevenness in a wide range of the face, and the effect of suppressing the inhalation of harmful substances can be further enhanced. .

  In addition, the inhalation suppression product 1 for harmful substances can be used for hair, for example, ear or neck.

  Moreover, in the said embodiment, although a chemical | medical agent is sprayed, it is not restricted to this, For example, you may make it apply | coat a finger | toe in cream form, gel form, and mousse form.

  As described above, the harmful substance inhalation suppression product according to the present invention can be used to suppress inhalation of harmful substances such as allergens and pathogenic viruses.

1 Inhalation suppression product for hazardous substances 2 Container 3 Spray mechanism A Charged substance B Titanium oxide (deactivator)
C Pollen D Pollen

Claims (3)

Inhalation control products for harmful substances that prevent humans from inhaling harmful substances such as allergens and pathogenic viruses,
A charged substance having a charge to adsorb the harmful substance by Coulomb force;
An inhalation-suppressing product for harmful substances, comprising: a deactivator for deactivating the harmful substances adsorbed on the charged substance. The inhalation-suppressing product for harmful substances according to claim 1,
A quenching agent is a rutile type titanium oxide, a harmful substance inhalation suppression product. The inhalation-suppressing product for hazardous substances according to claim 1 or 2,
The charged substance and the quencher are dispersed in a liquid,
An inhalation-suppressing product for harmful substances, characterized by having a spraying mechanism for spraying a liquid in which the charge substance and the deactivator are dispersed.

Images